PPARδ Expression and Prognosis in Resected Pancreatic Cancer: A Retrospective Single-Centre Study

Abstract

Background: Pancreatic cancer remains one of the most lethal malignancies, with limited curative options and poor long-term outcomes. Nuclear receptors, including PPAR{delta}, have been implicated in tumour progression. Methods: Retrospectively, we analysed 25 resected pancreatic cancer specimens from patients undergoing Whipple!s procedure (pancreatoduodenectomy) between 2000 and 2009. Immunohistochemistry was performed for PPAR{delta}. Tumour and stromal staining were assessed and correlated with clinicopathological features and survival data. Results: PPAR{delta} expression was observed in the majority of samples. This preliminary analysis suggests that PPAR{delta} expression is associated with adverse clinicopathological features and poorer survival. Conclusions: PPAR{delta} immunohistochemistry may identify a subset of pancreatic cancers with more aggressive biology. Larger studies are warranted to validate these findings.

Adjuvant alectinib versus crizotinib in completely resected ALK-positive non-small-cell lung cancer: a real-world retrospective cohort study
Translational Lung Cancer Research31 Aug 2026Peer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
Association Between Tumor Budding and Lymph Node Metastasis in Surgically Resected Colon Cancer: A Retrospective Observational Study
Alisina Bulut, Muhammed İkbal Akın, Beril Kara Esen +4
Medicina (Kaunas, Lithuania)25 Sep 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC
Larger Non-metastatic No. 8 Lymph Node Size Is Associated With Favorable Prognosis After Pancreaticoduodenectomy for Pancreatic Cancer.
Taro Sakamoto, Takeshi Gocho, Masashi Tsunematsu +10
Cancer diagnosis & prognosis1 Nov 2026Peer-reviewedCC BY-NC-NDFull textOncologyEurope PMCPMC
Macrophage-induced ferritin expression protects pancreatic cancer cells from ferroptosis
Eric C. Cheung, Meng-Han Wu, Wen-Chi Cheng +3
Cell Reports1 Oct 2026Peer-reviewedCC BY 4.0General medicineCrossref
Clinical characteristics and prognosis of T1N0M1 lung cancer: a population-based retrospective study
Weixu Sun, Chengxin Zhu, Xinping Li +2
Scientific Reports12 Oct 2026Peer-reviewedCC BY-NC-ND 4.0Full textGeneral medicineCrossref

Cite

BibTeX RIS

BibTeX

@misc{adamson2026pparδ,
  title = {{PPARδ Expression and Prognosis in Resected Pancreatic Cancer: A Retrospective Single-Centre Study}},
  author = {D. J. A. Adamson and S. V. Walsh and I. S. Tait and C. N. Palmer},
  howpublished = {bioRxiv},
  year = {2026},
  month = sep,
  doi = {10.64898/2026.09.08.750098},
  url = {https://www.biorxiv.org/content/10.64898/2026.09.08.750098v1},
  note = {CC BY},
}

RIS

TY  - UNPB
TI  - PPARδ Expression and Prognosis in Resected Pancreatic Cancer: A Retrospective Single-Centre Study
AU  - D. J. A. Adamson
AU  - S. V. Walsh
AU  - I. S. Tait
AU  - C. N. Palmer
PY  - 2026
DA  - 2026/09/08
PB  - bioRxiv
DO  - 10.64898/2026.09.08.750098
UR  - https://www.biorxiv.org/content/10.64898/2026.09.08.750098v1
AB  - Background: Pancreatic cancer remains one of the most lethal malignancies, with limited curative options and poor long-term outcomes. Nuclear receptors, including PPAR{delta}, have been implicated in tumour progression. Methods: Retrospectively, we analysed 25 resected pancreatic cancer specimens from patients undergoing Whipple!s procedure (pancreatoduodenectomy) between 2000 and 2009. Immunohistochemistry was performed for PPAR{delta}. Tumour and stromal staining were assessed and correlated with clinicopathological features and survival data. Results: PPAR{delta} expression was observed in the majority of samples. This preliminary analysis suggests that PPAR{delta} expression is associated with adverse clinicopathological features and poorer survival. Conclusions: PPAR{delta} immunohistochemistry may identify a subset of pancreatic cancers with more aggressive biology. Larger studies are warranted to validate these findings.
ER  -

Abstract

Related

Cite